Role of Akkermansia muciniphila in nonalcoholic fatty liver disease
- VernacularTitle:嗜黏蛋白阿克曼菌在非酒精性脂肪性肝病中的作用
- Author:
Liting ZHENG
1
;
Zhe WANG
1
;
Yuchun CHEN
1
;
Shanshan LIU
1
;
Youcheng XIE
1
;
Chuyi LI
1
;
Xiaohui YU
1
Author Information
- Publication Type:Review
- Keywords: Non-alcoholic Fatty Liver Disease; Akkermansia; Therapeutics
- From: Journal of Clinical Hepatology 2024;40(3):594-599
- CountryChina
- Language:Chinese
- Abstract: Nonalcoholic fatty liver disease （NAFLD） has become the most common chronic liver disease in the world， and it is also one of the main causes of liver cirrhosis and hepatocellular carcinoma， so it is particularly important to curb the development and progression of NAFLD in a timely manner. However， due to its complex pathogeneses， there are currently no effective methods for radical treatment. As a new generation of probiotics， Akkermansia muciniphila （Akk bacteria） can improve metabolic disorders of the body， and more and more studies have shown that Akk bacteria have a potential therapeutic effect on metabolic diseases， especially NAFLD. Therefore， this article briefly reviews the mechanism of action of Akk bacteria in NAFLD， in order to provide new ideas for improving the treatment of NAFLD and creating new therapies.
